Cargando…

Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab

OBJECTIVE: To compare drug survival on adalimumab, etanercept and infliximab in patients with rheumatoid arthritis (RA). METHODS: Patients with RA (n=9139; 76% women; mean age 56 years) starting their first tumour necrosis factor (TNF) inhibitor between 2003 and 2011 were identified in the Swedish B...

Descripción completa

Detalles Bibliográficos
Autores principales:	Neovius, M, Arkema, E V, Olsson, H, Eriksson, J K, Kristensen, L E, Simard, J F, Askling, J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2015
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4316855/ https://www.ncbi.nlm.nih.gov/pubmed/24285495 http://dx.doi.org/10.1136/annrheumdis-2013-204128

Ejemplares similares

Cost-Effectiveness Analysis of Biopharmaceuticals for Treating Rheumatoid Arthritis: Infliximab, Adalimumab, and Etanercept
por: Gholami, Ahmad, et al.
Publicado: (2021)

Mapping the certolizumab pegol epitope on TNF and comparison with infliximab, adalimumab and etanercept
por: Henry, Alistair I, et al.
Publicado: (2011)

Review of Eight Pharmacoeconomic Studies of the Value of Biologic DMARDs Adalimumab, Etanercept, and Infliximab) in the Management of Rheumatoid Arthritis
por: Doan, Quan V., et al.
Publicado: (2006)

Casual effect of methotrexate+etanercept/infliximab on survival of patients with rheumatoid arthritis
por: Akhlaghi, Saeed, et al.
Publicado: (2019)

Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis
por: Hebeisen, Monika, et al.
Publicado: (2019)

Effectiveness of dose reduction of etanercept and adalimumab in patients with rheumatoid arthritis
por: Martínez-Pérez, Rosalía, et al.
Publicado: (2011)

TNF-α Promoter Polymorphisms Predict the Response to Etanercept More Powerfully than that to Infliximab/Adalimumab in Spondyloarthritis
por: Liu, Jing, et al.
Publicado: (2016)

Clinical and economic efficiency to reduce dose etanercept and adalimumab in patients with rheumatoid arthritis
por: Martínez-Pérez, Rosalía, et al.
Publicado: (2012)

Restoration of Default Blood Monocyte-Derived Macrophage Polarization With Adalimumab But Not Etanercept in Rheumatoid Arthritis
por: Paoletti, Audrey, et al.
Publicado: (2022)

Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial
por: Eriksson, Jonas K, et al.
Publicado: (2015)

Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis
por: van Vollenhoven, Ronald F, et al.
Publicado: (2016)

Ankylosing Spondylitis and Rheumatoid Arthritis: Serum Levels of TNF-α and Its Soluble Receptors during the Course of Therapy with Etanercept and Infliximab
por: Schulz, Martin, et al.
Publicado: (2014)

Effects of Etanercept and Adalimumab on Serum Levels of Cartilage Remodeling Markers in Women with Rheumatoid Arthritis
por: Szeremeta, Anna, et al.
Publicado: (2023)

Dose Escalation and Co-therapy Intensification Between Etanercept, Adalimumab, and Infliximab: The CADURA Study
por: Thorne, Carter, et al.
Publicado: (2017)

Infliximab improves vascular stiffness in patients with rheumatoid arthritis
por: Wong, M, et al.
Publicado: (2008)

Multiomics and Machine Learning Accurately Predict Clinical Response to Adalimumab and Etanercept Therapy in Patients With Rheumatoid Arthritis
por: Tao, Weiyang, et al.
Publicado: (2020)

Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment
por: Strand, Vibeke, et al.
Publicado: (2012)

The Canadian Methotrexate and Etanercept Outcome Study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis
por: Pope, Janet E, et al.
Publicado: (2014)

Therapy with soluble TNF receptor (etanercept) induces apoptosis in rheumatoid arthritis (RA) synovium
por: Catrina, AI, et al.
Publicado: (2003)

Satisfaction with Subcutaneous Golimumab and its Auto-Injector among Rheumatoid Arthritis Patients with Inadequate Response to Adalimumab or Etanercept
por: Dehoratius, Raphael J., et al.
Publicado: (2018)

Independent Candidate Serum Protein Biomarkers of Response to Adalimumab and to Infliximab in Rheumatoid Arthritis: An Exploratory Study
por: Ortea, Ignacio, et al.
Publicado: (2016)

Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment
por: Bessette, Louis, et al.
Publicado: (2017)

The Effect of Dose Escalation on the Cost-Effectiveness of Etanercept and Adalimumab with Methotrexate Among Patients with Moderate to Severe Rheumatoid Arthritis
por: Incerti, Devin, et al.
Publicado: (2020)

Is drug discontinuation risk of adalimumab compared with etanercept affected by concomitant methotrexate dose in patients with rheumatoid arthritis?
por: Chen, Hsin-Hua, et al.
Publicado: (2016)

Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study
por: Combe, B, et al.
Publicado: (2008)

Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept
por: Crnkic, Meliha, et al.
Publicado: (2003)

Additional effect of etanercept or infliximab on the liver function tests of patients with rheumatoid arthritis: a cohort study
por: Akhlaghi, Saeed, et al.
Publicado: (2018)

Etanercept in the treatment of rheumatoid arthritis
por: Haraoui, Boulos, et al.
Publicado: (2007)

Etanercept for Treating Rheumatoid Arthritis
por: Moreland, Larry W
Publicado: (2000)

Adalimumab regulates intracellular TNFα production in patients with rheumatoid arthritis
por: Zamora-Atenza, Carlos, et al.
Publicado: (2014)

Antibodies to Infliximab and Adalimumab in Patients with Rheumatoid Arthritis in Clinical Remission: A Cross-Sectional Study
por: Eng, Grith P., et al.
Publicado: (2015)

Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden
por: Kristensen, Lars Erik, et al.
Publicado: (2006)

Treatment Patterns and Costs in Biologic DMARD-Naive Patients with Rheumatoid Arthritis Initiating Etanercept or Adalimumab with or Without Methotrexate
por: Tkacz, Joseph, et al.
Publicado: (2020)

Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate
por: Kavanaugh, A, et al.
Publicado: (2008)

Methotrexate Reduced TNF Bioactivity in Rheumatoid Arthritis Patients Treated with Infliximab
por: Dénarié, Delphine, et al.
Publicado: (2017)

Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study
por: Takeuchi, Tsutomu, et al.
Publicado: (2014)

Cohort profile: systemic lupus erythematosus in Sweden: the Swedish Lupus Linkage (SLINK) cohort
por: Arkema, Elizabeth V, et al.
Publicado: (2015)

An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status
por: van der Bijl, Arie E., et al.
Publicado: (2008)

Psoriatic Arthritis That Responded Dramatically When Infliximab Was Switched to Adalimumab
por: Ohshima, Yuichiro, et al.
Publicado: (2013)

Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)
por: Mease, P J, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_15otpufl4pvli011jakbjih7hq